Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency 1Pancreatic Neoplasms 1Neoplasms 1Liver Diseases 1Adenocarcinoma 1

Interventions

trifluridine tipiracil drug combination 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1linifanib 1ledipasvir, sofosbuvir drug combination 1fisogatinib 1ficlatuzumab 1durvalumab 1avelumab 1atezolizumab 1Trabectedin 1Sorafenib 1Ramucirumab 1Irinotecan 1Immunotherapy 1Electroporation 1Dexamethasone 1Bevacizumab 1Azacitidine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liver Diseases × rubitecan × Clear all
NCT00113113 2024-08-02

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Astex Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled

Liver Diseases, Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡